Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Foresite Capital
Deal Size : $92.0 million
Deal Type : Financing
Details : Investment from Foresite Capital and Arch Venture Partners will support platform development and therapeutic programs focused on inflammatory disease and cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 13, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Foresite Capital
Deal Size : $92.0 million
Deal Type : Financing